News and Announcements
Actinogen Receives US FDA Feedback to Enhance Alzheimers Study
- Published June 08, 2016 11:31AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
8th June 2016, ASX Announcement
Highlights:
- Productive interaction with the US Food and Drug Administration (FDA)
- Protocol enhancement will strengthen the value of the Phase II trial
- Harmonising Australian and UK trial with US FDA increases potential global value
- Fits into broader US strategy of medical publications slated for 2H16 and US investor campaign in 2H16
Actinogen Medical Limited (Actinogen Medical, ASX: ACW) is pleased to announce productive progress with the US Food and Drug Administration (FDA) to enhance the safety profile of XanADu, the Phrase II trial of its lead Alzheimer’s drug candidate, Xanamem™.
Good progress has been made with the Actinogen Medical team towards securing final US FDA approval under an Investigational New Drug (IND) for the Phase II study.
To view the full announcement, please click on the button below.
Company Updates
The Index Approach in Early-Stage Venture Capital: Reconsidered
The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]
The Future Is Now: The Evolution of Dealflow with Wholesale Investor
If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]
Investability of a Startup: A Comprehensive Guide for Angels and High-Net Worth Investors
Venturing into the Startup Scene Let’s dive into the intriguing world of startups. It’s a thrilling ride, isn’t it? Like finding a pearl in an ocean, spotting a promising startup amidst a sea of businesses is no easy task. This guide aims to light the way, focusing on the “The Investability of a Startup: 7 […]
Backed By Leading Investment Groups and Family Offices
